Last reviewed · How we verify
NCT07168265: EffAndonOS
The Effects of Androgen Replacement Therapy on Tear Osmolarity and Ocular Surface Parameters in Androgen Deficiency
NA trial testing androgen replacement therapy in Androgen Deficiency in 77 participants. Completed in 15 June 2025.
30 August 2020
Quick facts
| Lead sponsor | Neon Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 77 |
| Start date | 1 January 2020 |
| Primary completion | 30 August 2020 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- androgen replacement therapy — full drug profile →
Conditions studied
- Androgen Deficiency — all drugs for Androgen Deficiency →
- Ocular Surface Disease — all drugs for Ocular Surface Disease →
- Tear Osmolarity — all drugs for Tear Osmolarity →
Sponsor
Neon Hospital
Who can join
Adults 18 to 75, male only, with Androgen Deficiency or Ocular Surface Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To evaluate tear osmolarity and ocular surface findings in men with androgen deficiency (AD) and assess changes after androgen replacement therapy (ART). Design: A prospective interventional study. Participants and Methods Right eyes of 77 male participants were evaluated in this study. Serum total testosterone level were measured, and participants were categorized as AD group (testicular hypofunction, n=37, testosterone level \<231 ng/dL) and control group (healthy controls, n=40, testosterone level \>346 ng/dL). The parameters including Aging Male Symptoms Scale(AMS), OSDI scores, Meibomian Gland Dysfunction- Grading System(MGD-GS) scores, corneal staining, tear break-up time(TBUT), Schirmer I/II tests, tear osmolarity, the depth (TMD), the height (TMH) and the area (TMA) of inferior tear meniscus were investigated. AD group received intramuscular testosterone every two weeks. Main Outcome Measures: The changes in the ocular surface parameters were investigated during the ART while comparing the values of these parameters between the AD and control groups at baseline, 6th and 18th weeks of the treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07168265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Androgen Deficiency
Currently open trials in the same condition.
- NCT04460872 — Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury · Phase 2 · recruiting
Other Neon Hospital trials
Trials by the same sponsor.
- NCT04342247 — Effects of External Testosteron Intake on the Choroid: Enhance-depth Imaging Optical Coherence Tomography Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07168265 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neon Hospital
- Last refreshed: 11 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07168265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing